| Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised … A Sezer, S Kilickap, M Gümüş, I Bondarenko, M Özgüroğlu, M Gogishvili, ... The Lancet 397 (10274), 592-604, 2021 | 636 | 2021 |
| Emerging targeted therapies in triple-negative breast cancer J Crown, J O'shaughnessy, G Gullo Annals of oncology 23, vi56-vi65, 2012 | 264 | 2012 |
| Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial M Gogishvili, T Melkadze, T Makharadze, D Giorgadze, M Dvorkin, ... Nature medicine 28 (11), 2374-2380, 2022 | 161 | 2022 |
| Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma N Walsh, A Larkin, S Kennedy, L Connolly, J Ballot, W Ooi, G Gullo, ... BMC urology 9, 1-7, 2009 | 118 | 2009 |
| Ophelia syndrome with metabotropic glutamate receptor 5 antibodies in CSF A Mat, H Adler, A Merwick, G Chadwick, G Gullo, JO Dalmau, N Tubridy Neurology 80 (14), 1349-1350, 2013 | 99 | 2013 |
| MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma L O'driscoll, N Walsh, A Larkin, J Ballot, WS Ooi, G Gullo, R O'CONNOR, ... Anticancer research 27 (4B), 2115-2120, 2007 | 92 | 2007 |
| BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications F Sclafani, G Gullo, K Sheahan, J Crown Critical reviews in oncology/hematology 87 (1), 55-68, 2013 | 83 | 2013 |
| Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: a review of the literature A Losurdo, S Rota, G Gullo, G Masci, R Torrisi, G Bottai, M Zuradelli, ... Critical reviews in oncology/hematology 113, 283-291, 2017 | 54 | 2017 |
| Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer G Gullo, M Zuradelli, F Sclafani, A Santoro, J Crown Annals of oncology 23 (8), 2204-2205, 2012 | 53 | 2012 |
| First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma ZG Leoni C, Gullo G, Resta N, Fagotti A, Onesimo R, Schwartz B, Kazakin J ... Am J Med Genet A 179 (7), 1319-1324, 2019 | 50 | 2019 |
| Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis N Walsh, S Kennedy, AM Larkin, D Tryfonopoulos, AJ Eustace, ... British journal of cancer 102 (7), 1157-1162, 2010 | 48 | 2010 |
| High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid M Zuradelli, G Masci, G Biancofiore, G Gullo, M Scorsetti, P Navarria, ... The oncologist 14 (5), 548-556, 2009 | 48 | 2009 |
| LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed … A Sezer, S Kilickap, M Gümüş, I Bondarenko, M Özgüroğlu, M Gogishvili, ... Annals of Oncology 31, S1182-S1183, 2020 | 40 | 2020 |
| Uveal melanoma in Ireland C Baily, V O’Neill, M Dunne, M Cunningham, G Gullo, S Kennedy, ... Ocular oncology and pathology 5 (3), 195-204, 2019 | 40 | 2019 |
| Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up G Murtagh, T Lyons, E O’Connell, J Ballot, L Geraghty, D Fennelly, ... Breast cancer research and treatment 156, 501-506, 2016 | 34 | 2016 |
| Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer F Sclafani, G Giuseppe, J Mezynksi, C Collins, J Crown Journal of Clinical Oncology 30 (26), e257-e259, 2012 | 30 | 2012 |
| Herpes infections in breast cancer patients treated with adjuvant chemotherapy G Masci, M Magagnoli, G Gullo, E Morenghi, I Garassino, M Simonelli, ... Oncology 71 (3-4), 164-167, 2007 | 30 | 2007 |
| HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer A Canonici, L Ivers, NT Conlon, K Pedersen, N Gaynor, BC Browne, ... Investigational new drugs 37, 441-451, 2019 | 29 | 2019 |
| Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-Lung 3 part 2 trial T Makharadze, M Gogishvili, T Melkadze, A Baramidze, D Giorgadze, ... Journal of Thoracic Oncology 18 (6), 755-768, 2023 | 28 | 2023 |
| LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) M Gogishvili, T Melkadze, T Makharadze, D Giorgadze, M Dvorkin, ... Annals of Oncology 32, S1328, 2021 | 27 | 2021 |
